A comprehensive line of toolbox reagents for the straightforward development of antibody screening and maturation assays
Several therapeutic antibody action mechanisms have already been described, as illustrated here by the ligand or cytokine blockage approach. This concept applies for the first therapeutic antibody developed for the treatment of inflammatory diseases. Infliximab neutralizes the tumor necrosis factor (TNF) and prevents it from activating its cognate receptor.
Cisbio Bioassays has optimized a comprehensive selection of ready-to-use antibodies and binders coupled to HTRF® fluorescent dyes. This large panel of conjugates enables multiple assays to be developed, and is a flexible approach for addressing a broad variety of therapeutic targets.